Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Multi-Arm Study of Magrolimab + Docetaxel in Solid Tumors
2020-005265-14Phase 2Active
- Sponsor
- Gilead Sciences
- Start
- Oct 2021
- Modality
- Vaccines & Immunotherapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of magrolimab in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), transitional cell carcinoma (TCC) and 1 more (4 cohorts), sponsored by Gilead Sciences. Primary endpoint: Incidence of adverse events and laboratory abnormalities. Started Oct 2021; status: active.
02
Drugs
magrolimab
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)transitional cell carcinoma (TCC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2020-005265-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005265-14.